Market Place
Sourcing Support
Centrexion`s knee pain drug fails two PhIII studies
29 Apr 2022 //
ENDPTS
With ex-Allergan CEO on board, OcuTerra nabs $35M for eye drops
10 Nov 2021 //
FIERCEBIOTECH
Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent
03 Dec 2019 //
GLOBE NEWSWIRE
Kindler`s Centrexion restarts IPO bid to fund phase 3 pain trial
20 Sep 2019 //
FIERCE BIOTECH
Jeff Kindler`s Centrexion renews bid to make public debut
19 Sep 2019 //
ENDPOINT NEWS
Centrexion farms out pain drug to Lilly in deal worth up to $998M
29 May 2019 //
FIERCE BIOTECH
Eli Lilly In-Licenses Non-Opioid Drug from Centrexion in $997 Million-Plus Deal
28 May 2019 //
BIOSPACE
A bruised Eli Lilly buys rights to Centrexion’s pain drug for $47.5M upfront
28 May 2019 //
ENDPTS
Centrexion`s Appoints Financial Executive Nick Harvey as Chief Financial Officer
30 Jul 2018 //
PRESS RELEASE
Centrexion`s Appoints Veteran Healthcare Innovator Joseph R. Swedish to its BOD
26 Jun 2018 //
PRESS RELEASE
Centrexion Announces CNTX-4975 and CNTX-6970 Clinical Data Presentations
19 Apr 2018 //
PRESS RELEASE
Centrexion Announces First Patient Dosed in Phase 3 Trial of CNTX-4975
21 Feb 2018 //
PRESS RELEASE
Centrexion Announces Fast Track Designation Granted by FDA to CNTX-4975
16 Jan 2018 //
PRESS RELEASE
Centrexion Raises $67 M; Launching Phase 3 Program for CNTX-4975 in Knee (OP)
02 Jan 2018 //
PRESS RELEASE
Centrexion to Present Clinical Data from Pipeline of Chronic Pain
29 Aug 2017 //
PRESS RELEASE
Centrexion to Present 6-Month Efficacy Data on CNTX-4975 for Chronic Pain
13 Aug 2017 //
PRESS RELEASE
Centrexion Provides Updates & Advancements Pipeline of Chronic Pain Treatments
18 Jul 2017 //
PRESS RELEASE
Centrexion Announces Oral Presentation of Six Month Efficacy Data on CNTX-4975
07 Jun 2017 //
PRESS RELEASE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.